Arcturus Bioscience, Inc. Presents Results From Two Gene Prognostic Biomarker Studies At 28th Annual San Antonio Breast Cancer Symposium
Published: Dec 06, 2005
CARLSBAD, Calif., Dec. 6 /PRNewswire/ -- Arcturus Bioscience will present results from two internal clinical studies validating the company's proprietary two gene index, HOXB13:IL-17BR (H:I Index), as a potential prognostic biomarker for the assessment of disease recurrence risk in breast cancer patients at the 28th Annual San Antonio Breast Cancer Symposium, taking place December 8-11, 2005.
Arcturus and Massachusetts General Hospital previously described the discovery of the H:I Index as a predictor of clinical outcome in breast cancer patients receiving hormonal therapy. At the Breast Cancer Symposium, Arcturus presents two independent studies with Mayo Clinic and the Baylor Breast Cancer Center that confirm this original finding. In the first study conducted at the Mayo Clinic, the H:I Index is shown to be significantly associated with outcome in samples from a prospective randomized trial of 206 breast cancer patients receiving hormonal therapy. In the second study, with the Baylor Breast Cancer Center, the H:I Index was analyzed in a retrospective set of 852 patients. Results from this study further demonstrate the clinical utility of the H:I Index as a prognostic factor in breast cancer patients.
Results from both studies will be presented at the Posters/Discussion Session entitled "Expression Profiles in Prognosis and Prediction."
Poster Title: A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Presenter: Matthew P. Goetz, M.D., Breast Clinic, Mayo Clinic, Rochester, MN Time: Saturday, December 10, 5:00 to 7:00 p.m. in Ballroom A Poster Title: The HOXB13:IL17BR Index as a prognostic factor for early breast cancer. Presenter: Mark G. Erlander, Ph.D., Arcturus Bioscience, San Diego, CA Time: Saturday, December 10, 5:00 to 7:00 p.m. in Ballroom A
About Arcturus Bioscience: The molecular diagnostic business unit of Arcturus Bioscience is developing clinically-relevant signatures associated with cancer. In addition to breast cancer, Arcturus has recently presented technology that enables the molecular classification of multiple cancer types.Arcturus Bioscience
CONTACT: Antonius Schuh of Arcturus, +1-760-579-0500
Web site: http://www.arctur.com//